Brief: Adicet Bio Highlights Preclinical Data Supporting IND Readiness For ADI-270
22/04/2024 21:47
April 22 (Reuters) - Adicet Bio Inc ACET.O :
* ADICET BIO HIGHLIGHTS PRECLINICAL DATA SUPPORTING IND
READINESS
FOR ADI-270 IN AN ORAL PRESENTATION AT THE AMERICAN SOCIETY OF
GENE AND CELL THERAPY (ASGCT) 27TH ANNUAL MEETING
* ADICET BIO INC - ADI-270 DEMONSTRATED ENHANCED FUNCTIONAL
POTENCY AND RESILIENCE IN TUMOR MICROENVIRONMENT
* ADICET BIO INC - ON TRACK TO FILE AN INVESTIGATIONAL NEW
DRUG
(IND) APPLICATION FOR ADI-270 IN 2Q 2024
* ADICET BIO INC - PRECLINICAL FINDINGS SHOWED ROBUST
ANTI-TUMOR
ACTIVITY OF ADI-270 IN MULTIPLE CD70-POSITIVE SOLID AND
HEMATOLOGICAL CANCER MODELS
Source text for Eikon: ID:nBw8prDtva
Further company coverage: ACET.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on ADICET Bio
See all newsNASDAQ RESUMED AT 09:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
Brief: Adicet Bio Announces Positive Safety And Efficacy Data From Prula-Cel (Formerly Adi-001) Study In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis
Brief: Adicet Bio Announces FDA Clearance Of Ind Application For Adi-212
Adicet Bio, Inc. Reports Results For The Quarter Ended June 30: Earnings Summary